(Date:11/19/2009)...ike to be able to charge their cell phones and oth... A recent discovery made by UC San Diego engineers...rs that could do just this. , In recent researc...ar Bandaru, a professor in the UCSD Department of ...raduate student Mark Hoefer, have found that artif...
(Date:11/19/2009)...Y., Nov. 19 Dr. Mate Hidvegi, inve...nds to a press release issued on November 17 by Bi...or making false and self-serving statements about ...r. Hidvegi stated from his office in Budapest, Hun...n Avemar does not apply to AveULTRA, www.aveultr...
(Date:11/19/2009)...., Nov. 19 Spherix Incor...ology for diabetes therapy, and a provider of tech...supplement, biotechnology and pharmaceutical compa...ual Meeting of Shareholders. ,, At the meeting,...EX ) elected the following members to the Board of...
(Date:11/19/2009)...v. 19 /PRNewswire/ - Aegera Therapeutics Inc. anno...andomized Phase 2B study of AEG35156, a targeted a...multiple oncology indications. ,, The study, en...the X-Linked Inhibitor of Apoptosis (XIAP) Antisen...tarabine and Idarubicin in AML Following Failure o...
Breaking Biology Technology:Nanotube defects equal better energy and storage systems 2American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2...e-FirstCall/ - Oncothyreon Inc. (NASDAQ:,ONTY) (TS...zation plan to,focus the Company,s resources on th... process development and manufacturing of Stimuvax...linical development of PX-12,beyond the ongoing tr...ntrate Oncothyreon,s efforts and available resourc...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced t...nt in a Phase 1 trial of CVT-3619, a novel oral co...diseases. The U.S. Food and Drug,Administration re...drug,application for CVT-3619, a partial A1 adenos...sess the safety and pharmacokinetic profile,of CVT...
...alidity of Purdue patents; Purdue licenses ...hs, STAMFORD, Conn., Sept. 2 Purdue Pharma L.P. ...Hazelwood, Missouri have,agreed to end the OxyCont...atent infringement lawsuit between them in the Uni...t of New York., According to the agreement, Malli...
Other Biology Technology:Oncothyreon announces prioritization plan for development programs 2Oncothyreon announces prioritization plan for development programs 3Oncothyreon announces prioritization plan for development programs 4Oncothyreon announces prioritization plan for development programs 5CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 2CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 3Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2Caveolin Sampler Kit from BD Biosciences Pharmingen
UCB Eosinophil Chip-IHC from 3H Biomedical AB
UCB MSC Cell Chip-IHC from 3H Biomedical AB
B Cell Chip-IHC from 3H Biomedical AB
Biology Products: